The ring is now worth $11 billion and sells blood tests. We said this would happen.

Oura, the Finnish smart-ring maker, announced today a $900 million round led by Fidelity at a valuation of about $11 billion — roughly double where it raised ten months ago. The numbers underneath are real: more than 5.5 million rings sold, more than $500 million in revenue last year, a target above $1 billion this year, and by one analyst's count about 80% of the smart-ring market. The company says a majority of its users have a chronic condition and about one in ten are healthcare providers. And the product is no longer a ring. It is a ring plus a $99 blood panel of some fifty biomarkers, drawn at a national lab chain, with results read back inside the app.

What changed since December. When we wrote about the ring last December, after its previous round, we said the business was a subscription attached to a sensor, and that the pressure of a venture valuation would push it from measuring your sleep toward diagnosing your body. That took ten months. The blood panel is the pivot point: once a wellness device sells a lab test, the data it collects has a medical question attached, and the answer to that question is more services. For the one in ten users who are clinicians, a panel in the app may be a convenience. For the rest, it is a second opinion that never stops being delivered.

Ben’s take

Doubling a valuation in ten months on a hardware business is unusual, and it tells you what investors are paying for: not rings, but the installed base and what can be sold into it. A biomarker panel is the first product; it will not be the last, because $11 billion has to be earned back from 5.5 million fingers. The next products will be whatever increases the number of things you worry about per month. I say that as someone who has sat on the boards that write these plans.

Loree’s take

A fifty-marker panel on a healthy person will flag two or three results outside the reference range, on average, by arithmetic alone — that is what a 95% range means across fifty tests. Those flags will arrive on a phone, at night, without a clinician in the room. I already see the patients who come in holding them. The ring's sleep score was a conversation starter. The blood panel is a conversation the app is starting without me.

Why it matters to a recovering optimizer. The ring's original promise was modest and defensible: notice your sleep. Today's round funds a different promise — know your body through a device — and that promise is the trap this site exists to name. A long healthy life does not require fifty biomarkers on a subscription. It requires the five things the ring was supposed to help you notice, which it still can, if you let it stay a ring.